Implementation of pre‐exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy
Open Access
- 18 October 2016
- journal article
- editorial
- Published by Wiley in Journal of the International AIDS Society
- Vol. 19 (7S6) , 21108
Abstract
Background: In this article, we present recent evidence from studies focused on the implementation, effectiveness and cost‐effectiveness of pre‐exposure prophylaxis (PrEP) for HIV infection; discuss PrEP scale‐up to date, including the observed levels of access and policy development; and elaborate on key emerging policy and research issues to consider for further scale‐up, with a special focus on lower‐middle income countries.Discussion: The 2015 WHO Early Release Guidelines for HIV Treatment and Prevention reflect both scientific evidence and new policy perspectives. Those guidelines present a timely challenge to health systems for the scaling up of not only treatment for every person living with HIV infection but also the offer of PrEP to those at substantial risk. Delivery and uptake of both universal antiretroviral therapy (ART) and PrEP will require nation‐wide commitment and could reinvigorate health systems to develop more comprehensive “combination prevention” programmes and support wider testing linked to both treatments and other prevention options for populations at highest risk who are currently not accessing services. Various gaps in current health systems will need to be addressed to achieve strategic scale‐up of PrEP, including developing prioritization strategies, strengthening drug regulations, determining cost and funding sources, training health providers, supporting user adherence and creating demand.Conclusions: The initial steps in the scale‐up of PrEP globally suggest feasibility, acceptability and likely impact. However, to prevent setbacks in less well‐resourced settings, countries will need to anticipate and address challenges such as operational and health systems barriers, drug cost and regulatory policies, health providers’ openness to prescribing PrEP to populations at substantial risk, demand and legal and human rights issues. Emerging problems will require creative solutions and will continue to illustrate the complexity of PrEP implementation.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (P30 AI36214)
This publication has 37 references indexed in Scilit:
- Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE‐C qualitative study in Johannesburg, South AfricaJournal of the International AIDS Society, 2014
- Early Experiences Implementing Pre-exposure Prophylaxis (PrEP) for HIV Prevention in San FranciscoPLOS Medicine, 2014
- Brief Sexual Histories and Routine HIV/STD Testing by Medical ProvidersAIDS Patient Care and STDs, 2014
- Adherence to Antiretroviral Prophylaxis for HIV Prevention: A Substudy Cohort within a Clinical Trial of Serodiscordant Couples in East AfricaPLOS Medicine, 2013
- Challenges in Providing Counselling to MSM in Highly Stigmatized Contexts: Results of a Qualitative Study from KenyaPLOS ONE, 2013
- Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet, 2013
- Combination implementation for HIV prevention: moving from clinical trial evidence to population-level effectsThe Lancet Infectious Diseases, 2013
- High Acceptability of HIV Pre-exposure Prophylaxis but Challenges in Adherence and Use: Qualitative Insights from a Phase I Trial of Intermittent and Daily PrEP in At-Risk Populations in KenyaAIDS and Behavior, 2012
- Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and WomenNew England Journal of Medicine, 2012
- Safety and Adherence to Intermittent Pre-Exposure Prophylaxis (PrEP) for HIV-1 in African Men Who Have Sex with Men and Female Sex WorkersPLOS ONE, 2012